Pasar al contenido principal

ESTUDIO DE LAS RESPUESTAS DE CELULAS PLASMATICAS DE INTESTINO EN INDIVIDUOS SANOS Y EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL

RTI2018-093894-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease

  • Tejedor Vaquero, Sonia|||0000-0003-2873-4981
  • Neuman, Hadas|||0000-0003-4098-7041
  • Comerma, Laura|||0000-0002-0249-4636
  • Marcos-Fa, Xavi|||0000-0002-4216-1123
  • Corral-Vazquez, Celia|||0000-0002-0621-4590
  • Uzzan, Mathieu|||0000-0002-7761-2879
  • Pybus, Marc|||0000-0002-6195-5738
  • Segura-Garzón, Daniel|||0000-0003-0210-9571
  • Guerra, Joana|||0000-0001-7185-9283
  • Perruzza, Lisa
  • Tachó-Piñot, Roser|||0000-0002-4641-1134
  • Sintes, Jordi|||0000-0002-1836-7076
  • Rosenstein, Adam
  • Grasset, Emilie K.|||0000-0002-9592-1640
  • Iglesias, Mar|||0000-0002-2274-4671
  • Gonzàlez-Farré, Mònica|||0000-0002-0653-0980
  • Lop Gros, Joan|||0000-0002-9442-5688
  • Patriaca-Amiano, Maria Evangelina|||0000-0003-1001-1910
  • Larrubia-Loring, Monica
  • Santiago Díaz, Pablo|||0000-0003-2219-7687
  • Perera-Bel, Júlia|||0000-0002-6809-132X
  • Berenguer-Molins, Pau|||0000-0002-0170-2931
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Varela, Encarna|||0000-0001-6334-9320
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Grassi, Fabio|||0000-0003-3348-1712
  • Guarner, Francisco|||0000-0002-4051-0836
  • Mehandru, Saurabh|||0000-0001-9781-2969
  • Márquez Mosquera, Lucía|||0000-0002-3182-9570
  • Mehr, Ramit|||0000-0002-4303-6834
  • Cerutti, Andrea|||0000-0003-3026-4704
  • Magri, Giuliana|||0000-0002-0163-3542
Tejedor Vaquero et al. show that gut IgA1 and IgA2 subclasses co-emerge early in life, largely derive from clonally related and somatically mutated plasma cells in adults, and show unique changes of both frequency and reactivity in inflammatory bowel disease. The human gut includes plasma cells (PCs) expressing immunoglobulin A1 (IgA1) or IgA2, two structurally distinct IgA subclasses with elusive regulation, function, and reactivity. We show here that intestinal IgA1 + and IgA2 + PCs co-emerged early in life, comparably accumulated somatic mutations, and were enriched within short-lived CD19 + and long-lived CD19 - PC subsets, respectively. IgA2 + PCs were extensively clonally related to IgA1 + PCs and a subset of them presumably emerged from IgA1 + precursors. Of note, secretory IgA1 (SIgA1) and SIgA2 dually coated a large fraction of mucus-embedded bacteria, including Akkermansia muciniphila. Disruption of homeostasis by inflammatory bowel disease (IBD) was associated with an increase in actively proliferating IgA1 + plasmablasts, a depletion in long-lived IgA2 + PCs, and increased SIgA1 + SIgA2 + gut microbiota. Such increase featured enhanced IgA1 reactivity to pathobionts, including Escherichia coli, combined with depletion of beneficial A. muciniphila. Thus, gut IgA1 and IgA2 emerge from clonally related PCs and show unique changes in both frequency and reactivity in IBD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses

  • Gutzeit, C.
  • Grasset, E.K.
  • Matthews, D.B.
  • Maglione, P.J.
  • Britton, G.J.
  • Miller, Haley
  • Magri, Giuliana|||0000-0002-0163-3542
  • Tomalin, L.
  • Stapylton, M.
  • Canales-Herrerias, P.
  • Sominskaia, M.
  • Guzman, Mauricio|||0000-0002-4447-2064
  • Pybus, Marc|||0000-0002-6195-5738
  • Tejedor Vaquero, Sonia|||0000-0003-2873-4981
  • Radigan, L.
  • Tachó-Piñot, Roser|||0000-0002-4641-1134
  • Nalda, A.M.
  • Prat, M.G.
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Dieli-Crimi, Romina|||0000-0003-3413-5133
  • Clemente, J.C.
  • Mehandru, S.
  • Suarez-Farinas, M.
  • Faith, J.J.
  • Cunningham-Rundles, C.
  • Cerutti, Andrea|||0000-0003-3026-4704
The gut microbiota enhances systemic immunoglobulin G (IgG) responses to vaccines, but it is unknown whether this effect involves IgA, which coats intestinal microbes. That IgA may amplify postimmune IgG production is suggested by the impaired IgG response to pneumococcal vaccines in some IgA-deficient patients. Here, we found that antipneumococcal but not total IgG production was impaired in mice with IgA deficiency. The positive effect of gut IgA on antipneumococcal IgG responses started very early in life and could implicate gut bacteria, as these responses were attenuated in germ-free mice recolonized with gut microbes from IgA-deficient donors. IgA could exert this effect by constraining the systemic translocation of gut antigens, which was associated with chronic immune activation, including T cell overexpression of programmed cell death protein 1 (PD-1). This inhibitory receptor may attenuate antipneumococcal IgG production by causing B cell hyporesponsiveness, which improved upon anti-PD-1 treatment. Thus, gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Albumin reprograms the B cell transcriptional landscape and improves neutrophil antimicrobial function in patients with decompensated cirrhosis

  • Clària, Joan
  • Marcos Fa, Xavi
  • Giarracco, Emma
  • Cerutti, Andrea, 1965-
  • Moreau, Richard
Background & aims: Patients with acutely decompensated (AD) cirrhosis are immunocompromised and particularly susceptible to infections. This study investigated the immunomodulatory actions of albumin by which this protein may lower the incidence of infections. Methods: Blood immunophenotyping was performed in 11 patients with AD cirrhosis and 10 healthy volunteers (HV). Bulk and single-cell RNA sequencing (scRNA-seq) and flow cytometry were performed in peripheral blood mononuclear cells (PBMCs) from 20 patients with AD cirrhosis and 34 HV exposed to albumin. Albumin's effects on degranulation, phagocytosis, chemotaxis, and swarming of neutrophils from six patients with AD cirrhosis and nine HV were assessed by measuring myeloperoxidase enzymatic activity, the engulfment of fluorescent-labeled Escherichia coli and zymosan, and interactions of neutrophils with Candida albicans at single-cell resolution in microfluidic chambers, respectively. Whole blood RNA sequencing (RNA-seq) analyses were performed in 49 patients admitted for severe AD cirrhosis, of whom 30 received albumin during hospitalization. Results: Compared with HV, patients with AD cirrhosis showed severe lymphopenia and defective neutrophil antimicrobial function. Bulk and scRNA-seq analyses revealed significantly (false discovery rate [FDR] <0.05) increased signatures related to B cells, myeloid cells, and CD4+ T cells in PBMCs incubated with albumin. Changes in the B cell population were confirmed by flow cytometry. Neutrophils exposed to albumin also exhibited augmented chemotactic and degranulation responses, enhanced phagocytosis, and increased pathogen-restrictive swarming. RNA-seq data analysis in patients who had received albumin revealed specific upregulation of signatures related to B cells and neutrophils together with transcriptional changes in CD4+ T cells (FDR <0.05). Conclusions: The finding that albumin promotes the transcriptional reprogramming and expansion of the B cell compartment and improves neutrophil antimicrobial functions indicates mechanisms that may lower the incidence of infections in patients with severe AD cirrhosis receiving albumin therapy. Impact and implications: Patients with acutely decompensated cirrhosis receiving albumin as treatment have a lower incidence of infections. The reason for this protection is currently unknown, but the present study provides data that support the ability of albumin to boost the antimicrobial functions of immune cells in these patients. Moreover, these findings encourage the design of controlled clinical studies specifically aimed at investigating the effects of albumin administration on the immune system., This research was supported by EF CLIF, a private, non-profit organization receiving unrestricted grants from Grifols and Fundació Privada Cellex. EF CLIF is a partner and/or coordinator of several European Union (EU) Horizon 2020 program projects (Nos. 825694 and 847949). This study was also supported by Ministerio de Ciencia e Innovacion/Agencia Estatal Investigación MCIN/AEI, PID2022-138970OB-I00 10.13039/501100011033/FEDER, UE (to JC) and RTI2018-093894-B-I00 (to AC). LJ-G has held an FPU PhD fellowship (FPU19/04886) from the Spanish Ministry of Science, Innovation and Universities. EW was an EF CLIF Research Fellow who received grants from Fundació Privada Cellex and the Fondation Bettencourt-Schueller. IH received a Marie Skłodowska-Curie grant agreement (No. 75451) from the EU’s Horizon 2020 Research and Innovation Program. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses

  • Gutzeit, Cindy
  • Magri, Giuliana, 1978-
  • Guzmán, Mauricio
  • Tejedor Vaquero, Sonia, 1988-
  • Tachó-Piñot, Roser
  • Cerutti, Andrea, 1965-
The gut microbiota enhances systemic immunoglobulin G (IgG) responses to vaccines, but it is unknown whether this effect involves IgA, which coats intestinal microbes. That IgA may amplify postimmune IgG production is suggested by the impaired IgG response to pneumococcal vaccines in some IgA-deficient patients. Here, we found that antipneumococcal but not total IgG production was impaired in mice with IgA deficiency. The positive effect of gut IgA on antipneumococcal IgG responses started very early in life and could implicate gut bacteria, as these responses were attenuated in germ-free mice recolonized with gut microbes from IgA-deficient donors. IgA could exert this effect by constraining the systemic translocation of gut antigens, which was associated with chronic immune activation, including T cell overexpression of programmed cell death protein 1 (PD-1). This inhibitory receptor may attenuate antipneumococcal IgG production by causing B cell hyporesponsiveness, which improved upon anti-PD-1 treatment. Thus, gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses., This work was supported by US National Institutes of Health grants P01 AI61093 to C.C.-R. and A.C., R01 DK123749 to A.C., J.J.F., and S.M., R01 DK114038 to J.C.C., K23 AI137183 to P.J.M., and R21AI168718 to E.K.G.; Crohn’s and Colitis Foundation CDA 877970 to E.K.G.; Ministerio de Ciencia, Innovación y Universidades grant RTI2018-093894-B-I00 and European Advanced grant ERC-2011-ADG-20110310 to A.C.; and the Institute of Health Carlos III-Miguel Servet research program to G.M.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses

  • Gutzeit, Cindy
  • Magri, Giuliana, 1978-
  • Guzmán, Mauricio
  • Tejedor Vaquero, Sonia, 1988-
  • Tachó-Piñot, Roser
  • Cerutti, Andrea, 1965-
The gut microbiota enhances systemic immunoglobulin G (IgG) responses to vaccines, but it is unknown whether this effect involves IgA, which coats intestinal microbes. That IgA may amplify postimmune IgG production is suggested by the impaired IgG response to pneumococcal vaccines in some IgA-deficient patients. Here, we found that antipneumococcal but not total IgG production was impaired in mice with IgA deficiency. The positive effect of gut IgA on antipneumococcal IgG responses started very early in life and could implicate gut bacteria, as these responses were attenuated in germ-free mice recolonized with gut microbes from IgA-deficient donors. IgA could exert this effect by constraining the systemic translocation of gut antigens, which was associated with chronic immune activation, including T cell overexpression of programmed cell death protein 1 (PD-1). This inhibitory receptor may attenuate antipneumococcal IgG production by causing B cell hyporesponsiveness, which improved upon anti-PD-1 treatment. Thus, gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses., This work was supported by US National Institutes of Health grants P01 AI61093 to C.C.-R. and A.C., R01 DK123749 to A.C., J.J.F., and S.M., R01 DK114038 to J.C.C., K23 AI137183 to P.J.M., and R21AI168718 to E.K.G.; Crohn’s and Colitis Foundation CDA 877970 to E.K.G.; Ministerio de Ciencia, Innovación y Universidades grant RTI2018-093894-B-I00 and European Advanced grant ERC-2011-ADG-20110310 to A.C.; and the Institute of Health Carlos III-Miguel Servet research program to G.M.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Albumin reprograms the B cell transcriptional landscape and improves neutrophil antimicrobial function in patients with decompensated cirrhosis

  • Clària, Joan
  • Marcos Fa, Xavi
  • Giarracco, Emma
  • Cerutti, Andrea, 1965-
  • Moreau, Richard
Background & aims: Patients with acutely decompensated (AD) cirrhosis are immunocompromised and particularly susceptible to infections. This study investigated the immunomodulatory actions of albumin by which this protein may lower the incidence of infections. Methods: Blood immunophenotyping was performed in 11 patients with AD cirrhosis and 10 healthy volunteers (HV). Bulk and single-cell RNA sequencing (scRNA-seq) and flow cytometry were performed in peripheral blood mononuclear cells (PBMCs) from 20 patients with AD cirrhosis and 34 HV exposed to albumin. Albumin's effects on degranulation, phagocytosis, chemotaxis, and swarming of neutrophils from six patients with AD cirrhosis and nine HV were assessed by measuring myeloperoxidase enzymatic activity, the engulfment of fluorescent-labeled Escherichia coli and zymosan, and interactions of neutrophils with Candida albicans at single-cell resolution in microfluidic chambers, respectively. Whole blood RNA sequencing (RNA-seq) analyses were performed in 49 patients admitted for severe AD cirrhosis, of whom 30 received albumin during hospitalization. Results: Compared with HV, patients with AD cirrhosis showed severe lymphopenia and defective neutrophil antimicrobial function. Bulk and scRNA-seq analyses revealed significantly (false discovery rate [FDR] <0.05) increased signatures related to B cells, myeloid cells, and CD4+ T cells in PBMCs incubated with albumin. Changes in the B cell population were confirmed by flow cytometry. Neutrophils exposed to albumin also exhibited augmented chemotactic and degranulation responses, enhanced phagocytosis, and increased pathogen-restrictive swarming. RNA-seq data analysis in patients who had received albumin revealed specific upregulation of signatures related to B cells and neutrophils together with transcriptional changes in CD4+ T cells (FDR <0.05). Conclusions: The finding that albumin promotes the transcriptional reprogramming and expansion of the B cell compartment and improves neutrophil antimicrobial functions indicates mechanisms that may lower the incidence of infections in patients with severe AD cirrhosis receiving albumin therapy. Impact and implications: Patients with acutely decompensated cirrhosis receiving albumin as treatment have a lower incidence of infections. The reason for this protection is currently unknown, but the present study provides data that support the ability of albumin to boost the antimicrobial functions of immune cells in these patients. Moreover, these findings encourage the design of controlled clinical studies specifically aimed at investigating the effects of albumin administration on the immune system., This research was supported by EF CLIF, a private, non-profit organization receiving unrestricted grants from Grifols and Fundació Privada Cellex. EF CLIF is a partner and/or coordinator of several European Union (EU) Horizon 2020 program projects (Nos. 825694 and 847949). This study was also supported by Ministerio de Ciencia e Innovacion/Agencia Estatal Investigación MCIN/AEI, PID2022-138970OB-I00 10.13039/501100011033/FEDER, UE (to JC) and RTI2018-093894-B-I00 (to AC). LJ-G has held an FPU PhD fellowship (FPU19/04886) from the Spanish Ministry of Science, Innovation and Universities. EW was an EF CLIF Research Fellow who received grants from Fundació Privada Cellex and the Fondation Bettencourt-Schueller. IH received a Marie Skłodowska-Curie grant agreement (No. 75451) from the EU’s Horizon 2020 Research and Innovation Program. The funders had no influence on the study design, data collection and analysis, decision to publish, or preparation of the manuscript.